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9 (AAV9)/hMECP2 has been shown to extend the lifespan of
Mecp2/y mice, but this delivery route induces liver toxicity
in wild-type (WT)mice. To reduce peripheral transgene expres-
sion, we explored the safety and efficacy of AAV9/hMECP2
injected into the cisterna magna (ICM). AAV9/hMECP2
(1 1012 viral genomes [vg]; ICM) extendedMecp2/y survival
but aggravated hindlimb clasping and abnormal gait pheno-
types. In WT mice, 1  1012 vg of AAV9/hMECP2 induced
clasping and abnormal gait. A lower dose mitigated these
adverse phenotypes but failed to extend survival of Mecp2/y
mice. Thus, ICM delivery of this vector is impractical as a treat-
ment for Rett syndrome (RTT). To improve the safety of
MeCP2 gene therapy, the gene expression cassette was modified
to include more endogenous regulatory elements believed to
modulate MeCP2 expression in vivo. In Mecp2/y mice, ICM
injection of the modified vector extended lifespan and was
well tolerated by the liver but did not rescue RTT behavioral
phenotypes. In WT mice, these same doses of the modified
vector had no adverse effects on survival or neurological pheno-
types. In summary, we identified limitations of the original
vector and demonstrated that an improved vector design ex-
tends Mecp2/y survival, without apparent toxicity.Received 24 February 2017; accepted 13 April 2017;
http://dx.doi.org/10.1016/j.omtm.2017.04.006.
Correspondence: Steven J. Gray, University of North Carolina (UNC) Gene
Therapy Center, Chapel Hill, NC 27599, USA.
E-mail: steven_gray@med.unc.eduINTRODUCTION
Rett Syndrome (RTT) is an X-linked neurodevelopmental disorder
associated with severe motor abnormalities and reduced lifespan in
a proportion of patients.1–3 RTT is caused by loss-of-function muta-
tions in methyl CpG-binding protein 2 (MECP2),4 a transcription
regulator that is highly expressed in neurons.5,6 Inactivating muta-
tions inMeCP2 can alter the expression of many genes and ultimately
disrupt neuronal morphology and circuitry.2,7–10 Adeno-associated
virus serotype 9 (AAV9) has been used to transfer wild-type (WT)
MECP2 to cells in vivo, extending survival and attenuating neurolog-
ical deficits in mouse models of RTT.11,12 These models include hemi-
zygousMecp2/y males as well as heterozygousMecp2+/ females that
are mosaic for MeCP2 expression.11,12 Due to their limited survival106 Molecular Therapy: Methods & Clinical Development Vol. 5 June 20
This is an open access article under the CC BY-NC-ND license (http(9 to 10 weeks) and severe phenotypes, Mecp2/y mice are often
used for early-stage assessment of putative pharmacological and ge-
netic treatments for RTT.11,12
One study, using a self-complementary (sc) AAV9/MeP229-
hMECP2-myc-BGHpA vector (hereafter termed the first-generation
vector AAV9/hMECP2(v1)), extended the survival of Mecp2/y
mice injected intravenously (IV) between postnatal day 28 (PND28)
and PND35.11 This IV gene therapy, however, resulted in high trans-
gene expression in the liver as well as significantly elevated levels of
alanine aminotransferase (ALT), an indicator of liver toxicity.11 After
IV treatment with 1  1011 viral genomes (vg) AAV9/hMECP2(v1),
the level of total MeCP2 expression (measured as copies MECP2
cDNA per b-actin cDNA) in WT liver was 6x greater than that
observed within the brain.11 This liver tropism and hepatic transgene
expression observed after IV treatment can be attributed to the AAV9
capsid13 and the use of a small endogenousMecp2 promoter fragment
(MeP229),11,14 respectively. We therefore concluded that AAV9/
hMECP2(v1) was a successful “proof-of-concept” vector whose design
and administration route would need to be optimized before it could
be considered for human translation.11
To bias transgene expression away from the liver, we decided to
assess the safety and efficacy of AAV9/hMECP2(v1) after injection
into the cerebrospinal fluid (CSF) of Mecp2/y and WT mice. In
the current study, we identify deleterious side effects (e.g., abnormal
gait and hindlimb clasping) observed after cisterna magna (ICM) de-
livery of AAV9/hMECP2(v1). Importantly, these side effects were
not observed after treatment with a control vector delivering EGFP.
To address the limitations of the previously published vector, we
designed a second-generation vector (AAV9/hMECP2(v2)) that, in17 ª 2017 The Authors.
://creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. ICM Delivery of AAV9/hMECP2(v1)
Extends the Lifespan of Mecp2–/y Mice, but with
Deleterious Side Effects
(A) One month after ICM injection of 1  1012 vg/mouse,
modest transduction efficiency is observed throughout
the brains of Mecp2/y mice. Above are confocal images
of myc+ cells (indicated by white arrows) in the hippo-
campus, brain stem, and thalamus. Merged images show
anti-myc immunoreactivity (green), anti-NeuN immuno-
reactivity (red), and DAPI+ nuclei (blue). (B) Left: trans-
duction efficiencies calculated for three brain regions.
Right: neuronal tropism calculated for three brain
regions. n = 2 injected Mecp2/y mice, with five to six
slices imaged per brain region. (C) AAV9/hMECP2(v1)
significantly extends the median lifespan of Mecp2/y
mice from 57 days to 84 days. #p = 0.01 (Gehan-
Breslow-Wilcoxon test) for treated Mecp2/y mice
(1  1012 vg/mouse, ICM) versus controls (0 vg/mouse,
ICM). The legend in (C) also applies to (D)–(G). (C–E)
Approximate injection time point indicated by black
arrows. (D) AAV9/hMECP2(v1) (red) decreased body
weight after ICM injection in 4- to 5-week-old mice.
(E) 1  1012 vg AAV9/hMECP2(v1) (red) worsens aggre-
gate behavior scores in Mecp2/y mice after ICM
administration. (D and E) Shaded area indicates
time during which scores for ICM cohorts (saline
versus 1  1012 vg) were significantly different. *p < 0.05.
(F and G) Specifically, 1  1012 vg AAV9/hMECP2(v1)
(ICM) aggravates limb clasping and abnormal gait in
Mecp2/y mice. p values (paired t test) for treated
Mecp2/y mice versus their pre-treatment scores: **p%
0.0002; *p% 0.002. p values (unpaired t test) comparing
virus- and saline-treated mice at a fixed time point: #p%
0.0006. (H) Examples of virus-treated mice with limb
clasping (mouse IDs 43, 47). The older saline-treated and
AAV9/GFP-treated Mecp2/y mice do not yet have hin-
dlimb clasping. Blue arrows point to curled toes and limbs
held closely against the body. (B and D–G) Data points are
mean ± SEM.
www.moleculartherapy.orgMecp2/y mice, increases weight (relative to that of saline-treated
Mecp2/y littermates) and extends survival without aggravating
behavioral phenotypes. In addition, the effective dose of AAV9/
hMECP2(v2) is well tolerated in WT mice after ICM administration.
RESULTS
IntraCSF Administration of AAV9/hMECP2(v1) Extends Survival
of Mecp2–/y Mice
To bias transduction toward the central nervous system (CNS), we
decided to shift from an IV to an intraCSF route of administration.
Prior to conducting extensive safety and efficacy studies, we assessed
neuronal tropismand transduction efficiency 3 to 4weeks after treating
Mecp2/y mice with 1 1012 vg AAV9/hMECP2(v1) via the ICM (Fig-
ures 1A and 1B). Consistent with the reported CNS expression profile
of the MeP229 promoter,14 we observed predominantly neuronal
expression of MeCP2-myc after ICM treatment of juvenile mice, with
multiple brain regions showing a modest percentage (20%–40%) of
transduced anti-myc immunopositive cells (Figures 1A and 1B).MolecuTo evaluate the efficacy of intraCSF MECP2 gene therapy in ju-
venile Mecp2/y mice (PND28-35), we injected 1  1012 vg AAV9/
hMECP2(v1) via the ICM route (a similar intraCSF dataset for lumbar
intrathecal [IT] injections is provided in Figure S1). At this dose,
AAV9/hMECP2(v1) extended the median survival of Mecp2/y
mice by 27 days or 47% (p = 0.01, Gehan-Breslow-Wilcoxon test)
(Figure 1C).
In addition to reduced survival,Mecp2/y mice exhibit a well-charac-
terized array of neurological phenotypes (e.g., hindlimb clasping,
abnormal gait, and abnormal breathing) and reduced bodyweight
compared to their WT littermates.11,15,16 Body weight and RTT-like
phenotypes for Mecp2/y mice were recorded prior to injection and
weekly thereafter using an established observational aggregate pheno-
typic severity scoring system.15 At 7 to 8 weeks of age,Mecp2/y mice
treated with 1  1012 vg/mouse (ICM) had lower body weights than
did saline-treated Mecp2/y mice (Figure 1D). At this dose, RTT-like
phenotype severity scores were significantly increased in ICM-treatedlar Therapy: Methods & Clinical Development Vol. 5 June 2017 107
Figure 2. Peripheral Transgene Expression Is Observed after ICM
Administration of AAV9/hMECP2(v1) in Mecp2–/y Mice
(A) Vector biodistribution in Mecp2/y mice. (B) Transgene expression in Mecp2/y
mice. (A and B) n = 3 saline-treated mice and n = 5 AAV9/hMECP2(v1)-treatedmice.
Data are mean ± SEM. CC, cervical spinal cord; LC, lumbar spinal cord; TC,
thoracic spinal cord.
Molecular Therapy: Methods & Clinical Developmentmice (p% 0.05, starting at 6 weeks of age) (Figure 1E). In particular,
two parameters (limb clasping and gait) were significantly affected at
8 weeks of age (versus pre-ICM clasping and gait scores at 4 weeks of
age and versus scores for saline-treated mice at 8 weeks of age) (Fig-
ures 1F and 1G). Because most saline-treated Mecp2/y mice did not
survive beyond 9 weeks, the pairwise analyses in Figures 1F and 1G
were limited to data observed at 4 and 8 weeks of age. A control vector
AAV9/MeP229-EGFP (1  1012 vg/mouse, ICM) did not appear to
hasten the development of hindlimb clasping inMecp2/y mice, indi-
cating that the adverse limb/gait changes were likely caused by
MeCP2-myc overexpression (Figure 1H).
Peripheral Transgene Expression Is Observed after IntraCSF
Delivery of AAV9/hMECP2(v1)
IV administration of AAV9/hMECP2(v1) (1  1011 vg) has previ-
ously been shown to cause liver toxicity in WT mice.11 To determine
if the transgene was expressed in the liver and other peripheral organs
after ICM administration, we conducted biodistribution and gene
expression analyses on samples from Mecp2/y mice treated with
1  1012 vg of AAV9/hMECP2(v1). Intracisternally delivered virus
escaped to the periphery, with 30 viral genome copies detected
per liver cell (Figure 2A). This observation is consistent with pub-
lished data demonstrating peripheral transgene biodistribution
after intraCSF administration of AAV.13,17 In general, one or more
viral genome copies were present per cell across multiple organs
(Figure 2A). Gene expression was highest in the liver and brain
(1MECP2 cDNA copy per b-actin cDNA in Figure 2B; see Figure S2108 Molecular Therapy: Methods & Clinical Development Vol. 5 June 20for liver toxicity data). By delivering vector directly into the CSF,
instead of systemically, we were able to diminish the levels of trans-
gene expression in liver tissue relative to those observed in brain tissue
(previously published systemic delivery yielded 6 greater total
expression in the liver than in the brain after IV treatment with
1  1011 vg11) (Figure 2B).
IntraCSF Administration of AAV9/hMECP2(v1) Induces
Deleterious Effects in WT Mice
To thoroughly evaluate the safety of intracisternally delivered
AAV9/hMECP2(v1), we also treated WTmice in parallel with treated
Mecp2/y mice. The virus-treated (1  1012 vg/mouse; ICM) WT
cohort had a significantly shorter lifespan compared to that of sa-
line-treatedWTmice (p = 0.04) (Figure 3A). At this dose, a significant
decrease in body weight was observed between 9 and 20 weeks of age
for WT mice treated ICM (Figure 3B). Importantly, administration
of AAV9/hMECP2(v1) led to a significant and persistent increase
(worsening) in aggregate phenotype scores (Figure 3C). In general,
WT mice treated with 1  1012 vg AAV9/hMECP2(v1) (ICM)
demonstrated a significant increase in severity scores for hindlimb
clasping and abnormal gait within 2 weeks after injection (Figures
3D and 3E; Movie S1). Similarly, WT mice treated intrathecally
with 1  1012 vg AAV9/hMECP2(v1) experienced weight loss and a
significant increase in aggregate phenotype severity scores, with sig-
nificant scores for limb clasping observed at 12 weeks of age (relative
to pre-treatment scores) (Figure S1).
Effective Doses of a Second-Generation Vector Appear to Be
Well-Tolerated in WT and Mecp2–/y Mice
The severe adverse effects observed in both Mecp2/y and WT mice
led us to conclude that the AAV9/hMECP2(v1) vector is not a viable
treatment option for RTT. We suspect that many of these symptoms
may result from improper hMeCP2-myc transgene regulation for two
reasons. First, identical treatment with a control vector encoding
EGFP (expressed under the truncated MeCP2 promoter MeP229)
does not cause these adverse effects (Figure 1H; Movie S1). Second,
transgenic mouse models of loss or overexpression of MeCP2 have
been shown to exhibit some overlap in phenotypic abnormalities,
including kyphosis, clasping, and decreased locomotor activity.18–22
Thus, it would be strategic for a second-generationMECP2 gene ther-
apy to incorporate additional endogenous control elements to poten-
tially allow for better regulation of transgene expression in a trans-
duced cell.
The MeP229 core promoter fragment lacks a number of putative
regulatory elements (REs) predicted to lie upstream in the MECP2
promoter region.23,24 These REs may be important in cell-type-spe-
cific regulation of MeCP2 expression. The opportunity to engineer
additional endogenous repressive elements into the gene expression
cassette was particularly appealing in light of the broad peripheral vec-
tor distribution observed after ICM injection (Figure 2). Therefore, we
designed a second-generation vector containing an extended pro-
moter (mMeP426), a modified 30 UTR incorporating the highly
conserved distal polyadenylation signal of MECP2, and a panel of17
Figure 3. ICMDelivery of AAV9/hMECP2(v1) Induces
Behavioral Abnormalities in WT Mice
(A) AAV9/hMECP2(v1) shortens WT lifespan. Because
WT and Mecp2/y mice were tested in parallel, Figures 3
and 1 present the same data for saline-treated controls.
#p = 0.04 (Gehan-Breslow-Wilcoxon test) for treated mice
(WT, 1  1012 vg, ICM) versus controls (WT, 0 vg, ICM).
(A–C) Injection time point is indicated by black arrows.
(B and C) Shaded areas indicate times during which
saline- and virus-treated cohorts had significantly
different body weights or behavior scores; *p < 0.05.
(B) 1  1012 vg (ICM) AAV9/hMECP2(v1) decreases
body weight. Green dashed line at 25 weeks indi-
cates the time point at which 50% of mice treated with
1  1012 vg AAV9/hMECP2(v1) (ICM) died. An increased
mean weight for survivors is observed after this point.
(C) In WT mice, 1  1012 vg AAV9/hMECP2(v1) in-
duces behavioral abnormalities that are similar to
those observed in Mecp2/y mice (compare to Figure 1).
Abnormalities persist until death. (D and E) AAV9/
hMECP2(v1) (ICM) aggravates limb clasping and
abnormal gait in WT mice. For clarity, only data for saline-
treated and 1  1012 vg v1-treated mice are shown.
p values (paired t test) for virus-treated WT mice versus
their pre-treatment scores: **p = 0.001; *p = 0.04.
p values (unpaired t test) comparing virus- and saline-
treated mice at a fixed time point: ##p % 0.0001;
#p = 0.02. (B–E) Data points are mean ± SEM.
www.moleculartherapy.orgmicroRNA (miRNA)-binding sites specific to miRNAs endogenous
to, and known to interact with, the MECP2 30 UTR (Figures 4A and
S3).25–30 Numerous other vector design variations to the hMECP2(v1)
cassette have been carefully tested by our colleagues, leading to the
development of the hMECP2(v2) cassette. These other vector designs
are described in a companion paper by Gadalla et al.31 in this issue of
Molecular Therapy – Methods & Clinical Development. For the re-
maining data described herein, we focus on intraCSF administration
of AAV9/hMECP2(v1) and AAV9/hMECP2(v2). Because IT and
ICM injections of AAV9/hMECP2(v1) yielded similar results in WT
mice (Figures 3 and S1), we decided to streamline our methods and
evaluated AAV9/hMECP2(v2) via ICM administration only.
After ICMadministrationofAAV9/hMECP2(v2),weobserved a signif-
icant increase inMecp2/y median survival (p% 0.01, Gehan-Breslow-
Wilcoxon test; 42% or 40% increase inmedian lifespan formice treated
ICM with 1  1010 or 1  1011 vg/mouse, respectively) (Figure 4B).
Importantly, these doses were 10- to 100-fold less than the effective
dose of the first-generation vector AAV9/hMECP2(v1) (Figure 1C).
Although 1 1010 and 1 1011 vg of AAV9/hMECP2(v2) were both
effective at extending lifespan, dose-dependent effects on body weightMolecular Therapy: Methodswere observed for treated Mecp2/y and
WT mice. AAV9/hMECP2(v2) administered at
1  1010 vg/mouse (ICM) increased Mecp2/y
body weight relative to that of saline-treated
Mecp2/y mice at 2 and 4 weeks post-injection(p % 0.05, t test comparing saline- and virus-treated mice at each
time point) (Figure 4C). Importantly, 1  1010 vg did not affect the
mean body weight of treated WT mice. Because WT cohorts treated
with saline or 1  1010 vg had nearly identical mean body weights,
data for saline-treated mice (Figure 4C) were offset to improve clarity
(see Figure 4 caption).WT animals treatedwith 1 1011 to 1 1012 vg
experienced decreased body weight beginning 1 month post-injection
(relative to the weight of saline-treated WT mice) (Figure 4C).
At 1  1012 vg (ICM), AAV9/hMECP2(v2) significantly increased
aggregate phenotype severity by increasing severity scores specifically
for hindlimb clasping and abnormal gait in both Mecp2/y and
WT mice (Figures 4D and S4). At 1  1010 to 1  1011 vg (ICM),
AAV9/hMECP2(v2) had no effect on the mean aggregate scores of
WT and Mecp2/y mice (Figure 4D). This lack of phenotypic rescue
in Mecp2/y mice was surprising in light of previously published
data showing that neonatal intracranial injections of AAV9/CBA-
hMeCP2-myc-SV40pA could ameliorate the onset of RTT-like
abnormalities, including motor dysfunction.11 These results may be
due to a number of factors (modest transduction efficiency, age of in-
jection, etc.). To better sort out potential treatment effects in more
detail, we conducted additional experiments in randomized, paired& Clinical Development Vol. 5 June 2017 109
Figure 4. IntraCSF Delivery of AAV9/hMECP2(v2)
Extends the Lifespan of Mecp2–/y Mice
(A) Cartoon of modified gene expression cassette. Figures
1, 3, and 4 present the same saline-treated control data.
(B) 1  1010 and 1  1011 vg AAV9/hMECP2(v2) extend
the median lifespan of Mecp2/y mice from 57 days to
81 days (#p = 0.01) and 80 days (#p = 0.001), respectively.
(B–D) Approximate injection time point indicated by
black arrows. (C) Left: gray arrows indicate times at which
1  1010 vg AAV9/hMECP2(v2) significantly increases
the mean body weight of Mecp2/y mice. Although
the mean weight for Mecp2/y mice (1  1010 vg AAV9/
hMECP2(v2)) continued to increase after 8 weeks of
age, significant differences (versus the weight of saline-
treated mice) were not observed presumably due to
the early deaths of saline-treated mice. Right: 1 1011 to
1  1012 vg AAV9/hMECP2(v2) decrease the mean body
weight of WT mice. Shaded areas indicate times during
which saline- and virus-treated cohorts had significantly
different body weights. To improve clarity, weight data for
saline-treated WTmice was offset by +1 g. (D) 1 1010 or
1  1011 vg modified vector does not rescue aggregate
behavior scores in Mecp2/y mice after intraCSF admin-
istration, and at 1 1012, it worsened behavioral scores in
Mecp2/y and WT mice (p % 0.05 beginning at 6 and
5 weeks of age for treated Mecp2/y and WT mice
[respectively] versus saline controls). (C and D) Data
points are mean ± SEM.
Molecular Therapy: Methods & Clinical Developmentlittermates to eliminate cross-litter variability. Historically, we
have observed variability in the phenotypic severity of Mecp2/y
mice from different litters as well as variability in the age at which
severe symptoms appear. Thus, we were concerned that noise in
the mean behavior scores could obscure meaningful phenotypic
differences within pairs of saline- and virus-treated littermates. We
therefore decided to run pairwise analyses of saline- and virus-treated
Mecp2/y littermates (Figure S5). In short, AAV9/hMECP2(v2)
(1 1010 to 1 1011 vg) significantly increased the peak body weight
and growth rate (post-treatment) ofMecp2/y mice relative to that of
their saline-treatedMecp2/y siblings (Figure S5; p = 0.0003 and 0.02,
respectively). In addition, the overall health of virus-treatedMecp2/y
mice appeared to decline more gradually (Figure S5; n = 8 pairs,
p = 0.03). Finally, early observations on treated mice suggested
some possible benefits that may not be captured using a standard-
ized RTT scoring system.15 To document this qualitatively, we
video-recorded pairs of saline- and virus-treated littermates weekly.
Videos for these littermate pairs are provided in the Supplemental
Information (Movies S2, S3, and S4). A striking feature of these
videos is the difference in spontaneous movement between saline-
and virus-treated mice. Unlike their saline-treated littermates,
AAV9/hMECP2(v2)-treated mice often walked, climbed, explored
their surroundings, and/or approached the camera without prompt-
ing. Ultimately, however, all treated mice eventually experienced a
decline in overall health and succumbed.
To investigate liver function after ICM administration of 1  1012 vg
AAV9/hMECP2(v2), we quantified levels of albumin, ALT, aspartate110 Molecular Therapy: Methods & Clinical Development Vol. 5 June 20aminotransferase (AST), and alkaline phosphatase (ALKP) in the
blood serum of treated Mecp2/y animals (Figure 5). Levels of each
marker were indistinguishable between saline- and virus-treated co-
horts (p = 0.8, 0.4, 0.4, and 0.9, respectively; Figure 5A). Bio-
distribution and gene expression data from treated Mecp2/y mice
showed that virus escaped to the periphery after ICM injection
(33 viral genome copies per liver cell; 0.07 MeCP2 cDNA copies
per b-actin cDNA; Figures 5B and 5C).
Hypothetically, the divergent safety and efficacy profiles of
intracisternally administered AAV9/hMECP2(v1) and AAV9/
hMECP2(v2) could potentially be due to differences in how
these two viral genomes regulate transgene expression in the
brain, liver, and/or other organs. After all, viral genomes were
found throughout the entire body 3 to 4 weeks after ICM injection
(Figures 2, 5, and S2). In Mecp2/y mice, AAV9/hMECP2(v2)
generated fewer cDNA copies per viral genome in the heart, liver,
and spinal cord (Figure 6). Interestingly, a 10-fold dose increase
(from 1  1011 vg to 1  1012 vg) for AAV9/hMECP2(v2) resulted
in decreased normalized transgene expression in the heart and
liver, suggesting the presence of a dose-dependent inhibitory feed-
back mechanism in these tissues (1E11 vg AAV9/hMECP2(v2)/
mouse: **p % 0.004 for heart, liver, and lumbar spinal cord;
*p = 0.04 for cervical spinal cord; 1E12 vg AAV9/hMECP2(v2)/
mouse: ##p = 0.001 for liver; #p % 0.05 for heart, cervical spinal
cord, and thoracic spinal cord) (Figure 6). Immunofluorescence an-
alyses also showed that transgene expression is more tightly regu-
lated by AAV9/hMECP2(v2) (versus that of AAV9/hMECP2(v1))17
Figure 5. Peripheral Transgene Expression without Hepatic Toxicity Is
Observed after ICM Administration of AAV9/hMECP2(v2) in Mecp2–/y mice
(A) Blood serum levels of liver toxicity indicators in saline and virus-treatedMecp2/y
mice. No significant differences were observed. p = 0.8 for albumin; p = 0.4 for ALT;
p = 0.4 for AST; p = 0.9 for ALKP. n = 5 mice per group. (B) Vector biodistribution in
Mecp2/y mice. High levels of vector DNA are observed in liver cells (relative to
background signal). (C) Transgene expression in Mecp2/y mice. (B and C) n = 3
saline-treated mice and 4 AAV9/hMECP2(v2)-treated mice (1  1012 vg/mouse).
(A–C) Data are mean ± SEM. CC, cervical spinal cord; LC, lumbar spinal cord; TC,
thoracic spinal cord.
Figure 6. AAV9/hMECP2(v2) Provides Tighter Regulation of Transgene
Expression
In Mecp2/y mice, the second-generation vector genome generates fewer cDNA
copies per viral genome in specific organs. n = 4 to 5 mice per treatment.
**p% 0.004 for heart, liver, and lumbar spinal cord; *p = 0.04 for cervical spinal cord;
##p = 0.001 for liver; #p% 0.05 for heart, cervical spinal cord, and thoracic spinal
cord. For clarity, p values are only shown for comparisons against mice treated with
1  1012 vg AAV9/hMECP2(v1). Data points are mean ± SEM. CC, cervical spinal
cord; LC, lumbar spinal cord; TC, thoracic spinal cord.
www.moleculartherapy.orgin WT liver tissue after ICM administration (1  1011 vg/mouse;
Figure 7A). Interestingly, ICM administration of AAV9/hMECP2
(v2) (1  1011 vg/mouse) resulted in more anti-myc immunopos-
itive hepatic cells in Mecp2/y mice than in WT mice (1.2% versus
0.2%, respectively; p = 0.04; Figures 7A–7C). Mecp2/y mice treated
with 1  1011 AAV9/hMECP2(v1) reached their natural endpoints
before these immunofluorescent analyses were conducted. Figure 6,
however, shows that the ratio of transcript to viral genome is more
tightly regulated by AAV9/hMECP2(v2) (versus that of AAV9/
hMECP2(v1)) in Mecp2/y liver tissue. Finally, our examination
of brain tissue provided fewer clues explaining the improved safety
of AAV9/hMECP2(v2). On a WT background, 1  1011 vg of
either AAV9/hMECP2(v1) or AAV9/hMECP2(v2) resulted in low
apparent transduction efficiencies, with predominantly neuronal
tropism (Figures 7D–7G).MolecuDISCUSSION
IV administration of AAV9/hMECP2(v1) has been previously shown
to extend the lifespan of Mecp2/y mice, but overexpression of
MeCP2 in the liver induced liver toxicity.11 We have now shown
that ICM administration of AAV9/hMECP2(v1) extends the lifespan
ofMecp2/y mice, with a more favorable biodistribution toward CNS
transduction compared to IV. Importantly, however, intracisternal
administration of 1  1012 vg AAV9/hMECP2(v1) still resulted in
potentially problematic peripheral transgene expression (Figure 2),
a trend toward elevated blood serum toxicity indicators (Figure S2),
and deleterious neurological side effects (Figures 1 and 3), which
were not seen in mice treated with an AAV9/EGFP control vector.
Increased severity of hindlimb clasping and abnormal gait were un-
expected, given the absence of these side effects in previously pub-
lished MeCP2 gene transfer studies.11,12,32 In light of these data,
our conclusion is that AAV9/hMECP2(v1) cannot move forward
in translational studies. Thus, we developed a second-generation
MeCP2 viral genome that included additional putative regulatory el-
ements from the endogenous MECP2 promoter and 30 UTR. By
modifying the viral genome, we were able to extend Mecp2/y sur-
vival with a 10- to 100-fold lower dose compared to that used for
the AAV9/hMECP2(v1) vector (Figures 1 and 4). This dose range
is especially beneficial for a gene therapy because it increases the like-
lihood of administering a safe, effective dose in vivo. This low dose
(1  1010 to 1  1011 vg injected ICM) is well tolerated by the liver
and does not increase severity scores for limb clasping and abnormal
gait in treatedMecp2/y or WT mice (Figures 5 and S4). Our second-
generation vector significantly improved peak body weight and acute
growth rate (post-treatment) in Mecp2/y mice (Figure S5). The
mechanism underlying the increased body weight is unclear. In
addition, our second-generation vector significantly attenuated the
deterioration in overall health of MeCP2-null mice (Figure S5).
Our overall conclusion is that the AAV9/hMECP2(v2) design pro-
vides a substantial improvement over the original design we previ-
ously published,11 conferring some benefit to Mecp2/y mice over alar Therapy: Methods & Clinical Development Vol. 5 June 2017 111
Figure 7. The hMECP2(v2) Viral Genome Tightly
Regulates Transgene Expression inWTLiver Tissue
after ICM Administration
(A) In WT mice, the hMECP2(v2) viral genome tightly
regulates transgene expression in the liver. Arrows point
to myc+ cells. (B and C) hMECP2(v2) drives transgene
expression in MeCP2 null liver tissue. (C) Percentage of
myc+ liver cells (versus all DAPI+ liver cells). n = 3–5 mice
and 9–15 imaged sections per group. (D–G) AAV9/
hMECP2(v1) and AAV9/hMECP2(v2) yield similar trans-
duction efficiencies and neuronal tropism in treated
WT mice. (A–G) A single dose (1  1011 vg/mouse) was
evaluated for AAV9/hMECP2(v1) and AAV9/hMECP2(v2).
(C–G) Data points are mean ± SEM.
Molecular Therapy: Methods & Clinical Development10-fold dynamic range (1 1010 to 1 1011 vg injected ICM), which
is also well-tolerated.
The mechanism behind the improved therapeutic index of AAV9/
hMECP2(v2) versus AAV9/hMECP2(v1) is unclear, although our
data points toward it providing generally more regulated expression.
We currently know that the modified viral genome reduces transgene
expression (as detected by immunofluorescence) in WT liver tissue at
the dose (1  1011 vg) and route in our study (Figure 7). In addition,
inMecp2/y mice, AAV9/hMECP2(v2) appears to regulate transgene
expression more tightly (than that of AAV9/hMECP2(v1)), with
fewer cDNA copies generated per viral genome in the heart, liver,
and spinal cord (AAV9/hMECP2(v1) compared against AAV9/
hMECP2(v2)) (Figure 6). Indeed, when we evaluated the liver safety
profile of 1 1012 vg AAV9/hMECP2(v2), we observed no difference
in the mean levels of liver toxicity markers (versus those of saline-
treated mice; Figure 5). Tighter regulation of transgene expression
is especially important in light of the broad peripheral biodistribution
observed for both vectors after ICM administration (Figures 2 and 5).
This tighter regulation is consistent with the inclusion of additional
silencing elements in the second-generation vector. However, the
exact mechanism (such as a specific miRNA target) underlying112 Molecular Therapy: Methods & Clinical Development Vol. 5 June 2017the tighter transgene regulation for AAV9/
hMECP2(v2) remains to be determined.
Importantly, neither AAV9/hMECP2(v1) nor
AAV9/hMECP2(v2) were able to completely
and permanently reverse the symptoms of
RTT in mice. Furthermore, at higher doses
(1  1012 vg injected ICM), the AAV9/
hMECP2(v2) vector induced deleterious
behavioral effects in WT mice, indicating an
upper tolerated dose between 1  1011 and
1  1012 vg in mice by this route. Thus,
third-generation vectors should be developed
with a goal of expanding this upper tolerated
dosing threshold and/or increasing the thera-
peutic benefit at lower doses. Given the dosing
limits determined in mice and the known sideeffects associated with overdosing, dose-ranging studies in large an-
imals that are carefully monitored for side effects would be war-
ranted before human translation should be considered. In closing,
this study suggests that the inclusion of regulatory elements that
help control levels of transgene expression in the CNS and periphery
may prove to be critical for intraCSF delivery of MeCP2 gene
therapy.
MATERIALS AND METHODS
Vectors
The complete names for hMECP2(v1) and hMECP2(v2) are self-com-
plementary MeP229-human MeCP2-myc-BGHpA11 and self-com-
plementary MeP426-human MeCP2-myc-RDH1pA, respectively.
Both gene expression cassettes encode the e1 isoform of MeCP2,
which is composed of exons 1, 3, and 4.24,33 The MeP426 promoter
includes additional putative regulatory elements that are absent
from the shorter truncated promoter MeP229.23 RDH1pA is a syn-
thetic 30 UTR containing 110 bp of the highly conserved MeCP2
distal polyadenylation signal34 and an upstream miRNA-binding
panel containing sites for three additional miRNAs endogenous
to the MECP2 30 UTR: miR-19, miR-22, and miR-132.25,28–30 Se-
quences for MeP426 and RDH1pA are provided in Figure S3. The
www.moleculartherapy.orgself-complementaryAAV9/MeP229-GFP-SV40pA vector has been
previously described.11
Animals
Animal studies at University of North Carolina (UNC) Chapel Hill
were conducted according to a protocol approved by the Institutional
Animal Care and Use Committee (IACUC). Mice were weaned at
PND28 and were provided food and water ad libitum. Both WT
and Mecp2/y mice were weaned at PND28 so that Mecp2/y mice
could achieve a viable weight (10 g) before weaning. Euthanasia
criteria have been previously described.11
Virus Production
Vectors were produced by triple transfection, iodixanol gradient
centrifugation, and ion exchange chromatography, as described for
the UNC Vector Core.35 Purified vectors were dialyzed in PBS
(350 mM final NaCl concentration) containing 5% D-sorbitol and
stored at80C until use. Thawed aliquots were subsequently stored
at 4C. A filter-sterilized solution of PBS (350 mM final NaCl concen-
tration) containing 5% D-sorbitol was used as vehicle and virus dilu-
tion buffer.
Injections
Mice were randomized into treatment groups and injected (ICM or
IT, vector or vehicle treated) between 28 and 35 days of age. For litter-
mate comparisons, vehicle and virus treatments were randomly as-
signed without any prior knowledge regarding each sibling’s body
weight or general physical condition. Percutaneous IT injections
were performed on non-anesthetized mice as described.36 Mice as-
signed to ICM cohorts were injected intraperitoneally with a sterile-
filtered solution of 1.25% Avertin (also known as tribromoethanol;
0.02 mL/g body weight) dissolved in 1x PBS prior to inhalational iso-
flurane anesthesia. Mice remained on inhalational anesthesia for the
duration of the surgery, which was completed using a sterile tech-
nique. An incision was made in the scalp, exposing the skull
and neck muscles. A 50-mL Hamilton syringe was used to deliver a
10-mL bolus injection into the cisterna magna. Vetbond tissue adhe-
sive (3M) was then used to close the incision. Injected mice were re-
turned to a recovery cage, where they remained until they were ambu-
latory. Injected mice had access to acetaminophen (200 mg/kg body
weight) in their drinking water (100 mL) for the next 48 hr.
Behavior Scoring
Behavior scoring was completed by an observer blinded to treatment
according to previously published guidelines.15 In short, mobility,
gait, hindlimb clasping, breathing, tremor, and general appearance
were each assessed on a scale of 0–2, with 12 being the maximum
aggregate score attainable. Videos of mice provided as supplemental
data were taken by an observer that was not blinded to treatment.
Immunofluorescent Analyses
Mice were perfused 3 to 4 weeks post-injection with 1x PBS, followed
by filtered 4% paraformaldehyde (PFA) (in 1 PBS, 2 mM NaOH,
pH 7.4). Brains were then fixed for an additional 48 hr at 4C.MolecuA vibrating microtome (Leica VT 1000S) was used to prepare
40-mM sections from liver and brain tissue. Sections were washed
in 50% ethanol, followed by three washes in 0.3 M PBS with 0.3%
Triton X-100. Sections were then transferred to 10mM sodium citrate
(pH 6, 85C, 30 min) for antigen retrieval, and then washed (three
times) prior to blocking for 1 hr at room temperature in 5% goat
serum (in 0.3 M PBS, 0.3% Triton X-100). Tissue sections were
then incubated with primary antibodies at 4C for 48 hr. Primary
antibody mixtures were chicken anti-myc antibody (Novus; 1:500)
mixed with either rabbit anti-mouse MeCP2 (Cell Signaling; 1:500)
or rabbit anti-mouse NeuN (Millipore; 1:500) in 5% goat serum. Sec-
tions were then washed three times and incubated with secondary an-
tibodies for at least 4 hr at room temperature (goat anti-chicken Alexa
Fluor 488 [1:1,000]; goat anti-rabbit Alexa Fluor 594 [1:1,000] in 0%
goat serum). After immunolabeling, sections were incubated with
DAPI (1:2,000, v/v) in 0.3 M PBS and 0.3% Triton X-100 for 1 hr
at room temperature. Sections were washed 3x prior to mounting
with ProLongGold AntifadeMountant with DAPI. Neuronal tropism
(or %NeuN+ cells) = 100xðNeuN + ;myc+ cells=all myc+ cellsÞ. Trans-
duction efficiencies were calculated as the percentage of total nuclei
that are also myc+. Apparent transduction efficiencies (or % myc+
cells) = 100xðmyc+ cells=all DAPI + cellsÞ . Cells within an 80x field
of view were counted, with multiple brain sections imaged per mouse.
Microscopy
All immunolabeled sections were imaged with a Zeiss 710 confocal
microscope at the UNC Confocal and Multiphoton Imaging Facility.
Biodistribution and Gene Expression
Biodistribution of viral genomes and gene expression analyses (using
mRNA as a source target) for saline- and virus-treatedMecp2/y mice
were performed according to previously published methods11 using
primers specific for humanMeCP2. Primer sequences were published
by Gadalla et al.11 Tissue was harvested 3 to 4 weeks post-ICM. To
assess how tightly transgene expression was regulated, we calculated
the following ratio per organ per mouse: ðhMeCP2 cDNA copies per
b actin cDNA=viral genome copies per host gDNAÞ.We then calcu-
lated the mean ratio across four to five mice per cohort.
Blood Serum Collection
Blood serum was collected 3 to 4 weeks post-ICM according to pre-
viously published methods.11 Serum testing of blinded samples was
completed by the Animal Clinical Chemistry Core at UNC.
Statistical Analyses
Graphpad Prism was used to generate Kaplan-Meier survival plots
and calculate p values for survival cohorts. Unpaired t tests or
paired t tests were performed as appropriate for all other statistical
calculations.
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